Abbott Laboratories (NYSE:ABT) is Town & Country Bank & Trust CO dba First Bankers Trust CO's 7th Largest Position

Town & Country Bank & Trust CO dba First Bankers Trust CO cut its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 11.7% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 46,977 shares of the healthcare product maker's stock after selling 6,236 shares during the period. Abbott Laboratories accounts for approximately 2.5% of Town & Country Bank & Trust CO dba First Bankers Trust CO's investment portfolio, making the stock its 7th biggest holding. Town & Country Bank & Trust CO dba First Bankers Trust CO's holdings in Abbott Laboratories were worth $6,231,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Redwood Park Advisors LLC purchased a new position in shares of Abbott Laboratories in the fourth quarter worth $25,000. Noble Wealth Management PBC acquired a new position in Abbott Laboratories during the fourth quarter valued at $26,000. NewSquare Capital LLC grew its holdings in Abbott Laboratories by 78.4% during the fourth quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker's stock worth $27,000 after acquiring an additional 105 shares during the period. WealthTrak Capital Management LLC purchased a new position in shares of Abbott Laboratories during the 4th quarter valued at approximately $28,000. Finally, Rialto Wealth Management LLC acquired a new position in shares of Abbott Laboratories in the fourth quarter worth about $29,000. Institutional investors and hedge funds own 75.18% of the company's stock.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, Director Sally E. Blount sold 2,600 shares of Abbott Laboratories stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total value of $337,116.00. Following the completion of the transaction, the director now directly owns 34,058 shares of the company's stock, valued at $4,415,960.28. The trade was a 7.09% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Lisa D. Earnhardt sold 91,167 shares of the stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $133.82, for a total transaction of $12,199,967.94. Following the sale, the executive vice president now directly owns 71,928 shares in the company, valued at $9,625,404.96. This represents a 55.90% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.46% of the company's stock.

Analysts Set New Price Targets

Several analysts have commented on the company. Wall Street Zen lowered Abbott Laboratories from a "strong-buy" rating to a "buy" rating in a report on Wednesday, February 12th. Barclays raised their price target on shares of Abbott Laboratories from $158.00 to $159.00 and gave the company an "overweight" rating in a research note on Thursday, April 17th. Wells Fargo & Company lifted their price objective on Abbott Laboratories from $136.00 to $147.00 and gave the stock an "overweight" rating in a report on Thursday, April 17th. Citigroup increased their target price on Abbott Laboratories from $135.00 to $160.00 and gave the company a "buy" rating in a report on Tuesday, March 4th. Finally, Royal Bank of Canada lifted their price target on Abbott Laboratories from $140.00 to $145.00 and gave the stock an "outperform" rating in a research note on Thursday, April 17th. Four investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $142.59.

Abbott Laboratories Trading Down 0.1%

Shares of NYSE ABT traded down $0.16 during midday trading on Monday, reaching $133.42. 1,921,139 shares of the stock were exchanged, compared to its average volume of 6,141,128. The stock has a market capitalization of $232.13 billion, a P/E ratio of 17.44, a PEG ratio of 2.52 and a beta of 0.74. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60. The company has a 50 day simple moving average of $130.46 and a 200 day simple moving average of $125.31. Abbott Laboratories has a twelve month low of $99.71 and a twelve month high of $141.23.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 EPS for the quarter, beating the consensus estimate of $1.07 by $0.02. The business had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.38 billion. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. As a group, equities analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.